Künnapuu Jaana, Bokharaie Honey, Jeltsch Michael
Drug Research Program, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland.
Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.
Biology (Basel). 2021 Feb 23;10(2):167. doi: 10.3390/biology10020167.
Specific proteolytic cleavages turn on, modify, or turn off the activity of vascular endothelial growth factors (VEGFs). Proteolysis is most prominent among the lymph-angiogenic VEGF-C and VEGF-D, which are synthesized as precursors that need to undergo enzymatic removal of their C- and N-terminal propeptides before they can activate their receptors. At least five different proteases mediate the activating cleavage of VEGF-C: plasmin, ADAMTS3, prostate-specific antigen, cathepsin D, and thrombin. All of these proteases except for ADAMTS3 can also activate VEGF-D. Processing by different proteases results in distinct forms of the "mature" growth factors, which differ in affinity and receptor activation potential. The "default" VEGF-C-activating enzyme ADAMTS3 does not activate VEGF-D, and therefore, VEGF-C and VEGF-D do function in different contexts. VEGF-C itself is also regulated in different contexts by distinct proteases. During embryonic development, ADAMTS3 activates VEGF-C. The other activating proteases are likely important for non-developmental lymphangiogenesis during, e.g., tissue regeneration, inflammation, immune response, and pathological tumor-associated lymphangiogenesis. The better we understand these events at the molecular level, the greater our chances of developing successful therapies targeting VEGF-C and VEGF-D for diseases involving the lymphatics such as lymphedema or cancer.
特定的蛋白水解切割开启、修饰或关闭血管内皮生长因子(VEGF)的活性。蛋白水解在淋巴管生成相关的VEGF-C和VEGF-D中最为显著,它们以前体形式合成,在激活其受体之前需要经过酶促去除其C端和N端前肽。至少有五种不同的蛋白酶介导VEGF-C的激活切割:纤溶酶、ADAMTS3、前列腺特异性抗原、组织蛋白酶D和凝血酶。除ADAMTS3外,所有这些蛋白酶也能激活VEGF-D。不同蛋白酶的加工产生不同形式的“成熟”生长因子,它们在亲和力和受体激活潜力方面存在差异。“默认”的VEGF-C激活酶ADAMTS3不激活VEGF-D,因此,VEGF-C和VEGF-D在不同情况下发挥作用。VEGF-C本身在不同情况下也受到不同蛋白酶的调节。在胚胎发育过程中,ADAMTS3激活VEGF-C。其他激活蛋白酶可能对非发育性淋巴管生成很重要,例如在组织再生、炎症、免疫反应和病理性肿瘤相关淋巴管生成过程中。我们对这些分子水平事件的理解越深入,就越有机会开发出针对VEGF-C和VEGF-D的成功疗法,用于治疗涉及淋巴管的疾病,如淋巴水肿或癌症。